Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (97)
July 28, 2008
-
Maurer's Healthcare Insight (96)
June 23, 2008
-
Maurer's Healthcare Insight (95)
May 19, 2008
-
Maurer's Healthcare Insight (94)
March 10, 2008
-
Maurer's Healthcare Insight (93)
February 18, 2008
-
Maurer's Healthcare Insight (92)
January 21, 2008
-
Maurer's Healthcare Insight (91)
December 24, 2007
-
Maurer's Healthcare Insight (90)
November 5, 2007
-
Maurer's Healthcare Insight (89)
October 8, 2007
-
Maurer's Healthcare Insight (88)
August 6, 2007
-
Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
-
Maurer's Healthcare Insight (86)
May 28, 2007
-
Maurer's Healthcare Insight (85)
April 16, 2007
-
Maurer's Healthcare Insight (84)
March 26, 2007
-
Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
-
Maurer's Healthcare Insight (83)
February 19, 2007
-
2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
-
Maurer's Healthcare Insight (82)/Questions from the Floor P. Reed Maurer
December 18, 2006
-
Maurer's Healthcare Insight (81)
November 20, 2006
-
Maurer's Healthcare Insight (80)
October 23, 2006
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…